Amber Therapeutics
PrivateLast Round
Series A
Jun 10, 2024
Total Funding Raised
$100M
Company Overview
Amber Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A round in June 2024.
Amber Therapeutics is a biotechnology company that develops innovative bioelectronic platforms for closed-loop therapies aimed at treating mixed urinary incontinence through targeted peripheral interventions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amber Therapeutics Comparables
Compare Amber Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Juniper Biomedical | 85% | |
| BlueWind Medical | 83% | |
| Neuspera Medical | 80% |
For institutional investors. Book with your work email.
Amber Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 10, 2024 | ||||
| Seed | Jan 24, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Amber Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Enterprise Associates | Series A |
| Lightstone Ventures | Series A |
| Oxford Science Enterprises | Series A, Seed |
| F-Prime Capital | Series A |
| UKRI Innovate UK | Seed |
| Intuitive Ventures | Series A |
| Oxford Science Enterprises | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Accelerating towards first Pivotal Trial for Picostim System.
- Jun 10, 2024
$100M round led by New Enterprise Associates (NEA)
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 11, 2026
Amber Tx is developing a closed-loop neuromodulation therapy system to treat mixed urinary incontinence, with its completed $100 million Series A supporting continued development.
For institutional investors. Book with your work email.
Amber Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Amber Therapeutics's valuation, stock price, and market status.
Is Amber Therapeutics a public or private company?
Amber Therapeutics is a private company.
What is the current stock price of Amber Therapeutics?
Amber Therapeutics is a private company, so its shares have no public market price. Caplight tracks Amber Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Amber Therapeutics worth (valuation)?
Valuation information for Amber Therapeutics is not publicly available.
Can I buy Amber Therapeutics stock?
Amber Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Amber Therapeutics's last funding round?
Amber Therapeutics's most recent funding round was Series A on June 10, 2024.
Who are the main investors in Amber Therapeutics?
Key investors in Amber Therapeutics include New Enterprise Associates.
Will Amber Therapeutics IPO soon?
No public IPO plans have been announced for Amber Therapeutics.
How can I track Amber Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Amber Therapeutics's shares on secondary markets.